GHO plans to increase its technology and service proposition following the completion of the acquisition, according to the company.

X-Chem's proprietary DNA-encoded library platform contains over 200 billion small molecules that it can leverage for drug discovery services.

Matt Clark, co-founder of X-Chem and its current senior vice president, will be named its chief executive officer (CEO). Rick Wagner, co-founder and CEO of X-Chem, will resign from the company.

Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...

AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...